Fanconi Anemia Clinical Trials 2024

Fanconi Anemia Clinical Trials 2024

Fanconi Anemia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in fanconi anemia clinical trials today.

Fanconi Anemia Clinical Trials

Here are the 6 most popular medical studies for fanconi anemia

Popular filter options for fanconi anemia trials

FA Clinical Trials

View 15 FA medical studies.

Fanconi Anemia Clinical Trials With No Placebo

View 15 fanconi anemia medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to fanconi anemia

What are the top hospitals conducting fanconi anemia research?

Fanconi anemia, a rare genetic disorder that affects bone marrow and increases the risk of cancer, has drawn the attention of several top hospitals conducting clinical trials. In Cincinnati, the Children's Hospital Medical Center is leading the charge with four active trials dedicated to fanconi anemia and a solid record of 10 completed studies since their first trial in 2004. Meanwhile, at the Masonic Cancer Center in Minneapolis, researchers are diligently working on two ongoing trials for this condition while having accomplished five previous investigations since initiating their first fanconi anemia trial in 2000.

In Stanford, California, both Stanford University and Lucille Packard Children's Hospital are making significant contributions to understanding and treating fanconi anemia. Stanford University currently hosts two active clinical trials for this disorder but has recorded only two all-time experiments thus far—although its pioneering efforts began as recently as 2020. Furthermore,Lucille Packard Children's Hospital made remarkable progress by launching their very first fanconi anemia trial in just three years from now; meanwhile they continue to push forward with one ongoing study focused on this challenging condition.

The M D Anderson Cancer Center based in Houston also joins these esteemed institutions with expertise in tackling fanconi anemia. They have conducted two all-time clinical trials for this rare genetic disease since recording their inaugural investigation back in 2007.Across different locations spanning from Ohio to Texas and Minnesota to California each hospital mentioned plays a crucial role not just within individual communities but collectively contributing towards scientific advancements across borders; ultimately bolstering hopes for individuals affected by fanconi anemia worldwide

Which are the best cities for fanconi anemia clinical trials?

When it comes to fanconi anemia clinical trials, several cities in the United States are at the forefront of research and innovation. Cincinnati, Ohio leads the way with 4 active trials investigating treatments such as Quercetin, Time-Restricted Feeding, and Peripheral blood stem cell therapy. Minneapolis, Minnesota follows closely behind with 3 ongoing studies focusing on factors like alcohol consumption and specific medications like FP-045 and G-CSF. Stanford, California also contributes significantly to fanconi anemia research with 3 active trials exploring potential breakthroughs like RP-L102 and JSP191. These cities offer individuals affected by fanconi anemia access to cutting-edge clinical trials that could provide new hope for effective treatments.

Which are the top treatments for fanconi anemia being explored in clinical trials?

Fanconi anemia is a rare genetic disorder, and clinical trials are actively exploring various treatment options. Prominent among these treatments are quercetin, RP-L102, time-restricted feeding, and JSP191. Quercetin, a dietary supplement, is being tested in two active trials for fanconi anemia since its first listing in 2012. Similarly, RP-L102 shows promise with two ongoing trials and three all-time trials since 2019. Another intriguing approach is time-restricted feeding with one active trial listed in 2022. Additionally, JSP191 has also entered the scene with one active trial following its introduction in 2021. These innovative avenues of research offer hope to individuals living with Fanconi anemia as scientists strive to find effective treatments for this challenging condition.

What are the most recent clinical trials for fanconi anemia?

Exciting advancements in clinical trials offer hope for individuals with Fanconi anemia, a rare genetic disorder. The most recent studies include FP-045 and JSP191, both currently in Phase 1 and Phase 2 stages of development. These innovative treatments became available on June 30, 2023, and December 7, 2021, respectively. Another notable trial is RP-L102, which reached Phase 2 and was made accessible to patients on July 15, 2020. Additionally, the drug Olaparib has shown promise during its Phase 2 trial that commenced on June 24th of the same year. These ongoing investigations highlight the dedication towards finding effective therapies for Fanconi anemia patients and provide encouragement for their well-being moving forward.

What fanconi anemia clinical trials were recently completed?

Recently completed clinical trials for Fanconi Anemia include:

  • A trial investigating the efficacy of gene therapy, sponsored by Stanford University School of Medicine and completed in October 2021.
  • A trial evaluating the use of hematopoietic stem cell transplantation, sponsored by Cincinnati Children's Hospital Medical Center and concluded in September 2021.
  • A trial exploring a combination therapy approach, involving growth factors and steroids, sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which was completed in January 2021. These recent clinical trials represent important advancements in understanding and treating Fanconi Anemia, offering hope to patients affected by this rare genetic disorder.